Plan addresses submission decline

J. G. D.
March 2011
Medical Marketing & Media;Mar2011, Vol. 46 Issue 3, p30
Trade Publication
The article reports on the plan of the Food and Drug Administration (FDA) to reverse a decline in new drug and biologic submissions and approvals in the U.S.


Related Articles

  • Herbal medicine at a crossroads Taylor, David // Environmental Health Perspectives;Sep1996, Vol. 104 Issue 9, p924 

    No abstract available.

  • Pipeline preview.  // Formulary;Jul2008, Vol. 43 Issue 7, p234 

    This article lists drugs whose position in the U.S. Food and Drug Administration approval process changed in 2008 including the pneumonia drug Tigecycline, the osteoporosis drug Bazedoxifene, and the ulcerative colitis drug Balsalazide.

  • FDA blames industry for slow approvals.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p34 

    Reports on the poor performance of Food and Drug Administration in approving developed drugs in the U.S. Delay in providing an approval letter; Factors contributing to the prolong of approval time; Review of products submitted by the pharmaceutical companies.

  • new drug application.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1583 

    An encyclopedia entry for "new drug application," which refers to an application requiring approval by the U.S. Food and Drug Administration (FDA) before any new drug is marketed to the public, is presented.

  • No. 10 Biosimilars Hit the U.S. Market. C. W. // Popular Science;Jan2015, Vol. 286 Issue 1, p45 

    The article reports that biosimilar drugs which are cheaper than the biologic drugs for treatment of diseases including cancer, arthritis, and multiple sclerosis would become available soon as the U.S. Food and Drug Administration approves.

  • FDA restructures new product review centers. Bouchie, Aaron // Nature Biotechnology;Oct2002, Vol. 20 Issue 10, p960 

    Reports on the U.S. Food and Drug Administration's (FDA) consolidation of the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). Sole authority over all new pharmaceutical products to be shouldered by CDER; Concern that regulations for...

  • Market watch: Upcoming market catalysts in Q3 2015. Tan, Clara // Nature Reviews Drug Discovery;Jul2015, Vol. 14 Issue 7, p451 

    The article reports on drug developments which are likely to be approved in 2015 third quarter by the U.S. Food and Drug Administration, including the sebelipase alfa for lysosomal acid lipase deficiency developed by Synageva and Roche's mitogen-activated protein kinase inhibitor cobimetinib.

  • FDA Plans to Revamp cGMP Rules. Wood, Andrew // Chemical Week;8/24/2002-9/4/2002, Vol. 164 Issue 34, p33 

    Deals with the plans of the U.S. Food and Drug Administration to change rules for drug manufacturing. Areas to be changed; Goals of the program; Comments on the plans.

  • Harmonizing Standards and Specifications. Wechsler, Jill // Pharmaceutical Technology North America;May2002, Vol. 26 Issue 5, p14 

    Reports the establishment of product specifications during drug development by the U.S. Food and Drug Administration. Efforts to streamline methods of documenting drug quality; Global specifications for the measurement of consistency of drug substances and products; Standards of drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics